Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity
Hua-Fei Li,1–3,* Cong Wu,4,* Ting Chen,5,* Ge Zhang,1 He Zhao,1 Chang-Hong Ke,1 Zheng Xu21International Joint Cancer Institute, Translation Medicine Institute, 2Planning Division, Scientific Research Department, 3Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-07-01
|
| Series: | International Journal of Nanomedicine |
| Online Access: | http://www.dovepress.com/construction-and-characterization-of-an-anti-cd20-mab-nanocomb-with-ex-peer-reviewed-article-IJN |
| _version_ | 1818858048539590656 |
|---|---|
| author | Li H Wu C Chen T Zhang G Zhao H Ke C Xu Z, |
| author_facet | Li H Wu C Chen T Zhang G Zhao H Ke C Xu Z, |
| author_sort | Li H |
| collection | DOAJ |
| description | Hua-Fei Li,1–3,* Cong Wu,4,* Ting Chen,5,* Ge Zhang,1 He Zhao,1 Chang-Hong Ke,1 Zheng Xu21International Joint Cancer Institute, Translation Medicine Institute, 2Planning Division, Scientific Research Department, 3Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, 4Department of Laboratory Diagnosis, Changhai Hospital, 5Department of Cardiology, Changhai Hospital, the Second Military Medical University, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherapy, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, caspase-dependent apoptosis, and lysosome-mediated programmed cell death (PCD), they could hardly be synchronously activated by any anti-CD20 mAb or mAb derivative until now. Herein, a novel mAb nanocomb (polyethylenimine polymer–RTX–tositumomab [PPRT nanocomb]) was firstly constructed through mass arming two different anti-CD20 mAbs (RTX and tositumomab) to one polymer by nanotechnology. Comparing with free mAbs, PPRT nanocomb possesses a comparable binding ability and reduced “off-rate” to surface CD20 of NHL cells. When treated by PPRT nanocomb, the caspase-dependent apoptosis was remarkably enhanced except for concurrently eliciting complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and lysosome-mediated PCD. Besides, “cross-cell link”-assisted homotypic adhesion by PPRT nanocomb further enhanced the susceptibility to PCD of lymphoma cells. Pharmacokinetic assays revealed that PPRT nanocomb experienced a relatively reduced clearance from peripheral blood compared with free antibodies. With the cooperation of all the abovementioned superiorities, PPRT nanocomb exhibits exceptionally excellent in vivo antitumor activities in both disseminated and localized human NHL xenotransplant models.Keywords: non-Hodgkin lymphoma, CD20, nanotechnology, rituximab, programmed cell death |
| first_indexed | 2024-12-19T08:50:06Z |
| format | Article |
| id | doaj.art-945480114bc1414b81e77681651ed775 |
| institution | Directory Open Access Journal |
| issn | 1178-2013 |
| language | English |
| last_indexed | 2024-12-19T08:50:06Z |
| publishDate | 2015-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj.art-945480114bc1414b81e77681651ed7752022-12-21T20:28:44ZengDove Medical PressInternational Journal of Nanomedicine1178-20132015-07-012015default4783479622880Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activityLi HWu CChen TZhang GZhao HKe CXu Z,Hua-Fei Li,1–3,* Cong Wu,4,* Ting Chen,5,* Ge Zhang,1 He Zhao,1 Chang-Hong Ke,1 Zheng Xu21International Joint Cancer Institute, Translation Medicine Institute, 2Planning Division, Scientific Research Department, 3Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, 4Department of Laboratory Diagnosis, Changhai Hospital, 5Department of Cardiology, Changhai Hospital, the Second Military Medical University, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: The CD20-directed monoclonal antibody rituximab (RTX) established a new era in the treatment of non-Hodgkin lymphoma (NHL); however, suboptimal response and/or resistance to RTX still limit its clinical merits. Although four effector mechanisms are validated to participate in CD20-based immunotherapy, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, caspase-dependent apoptosis, and lysosome-mediated programmed cell death (PCD), they could hardly be synchronously activated by any anti-CD20 mAb or mAb derivative until now. Herein, a novel mAb nanocomb (polyethylenimine polymer–RTX–tositumomab [PPRT nanocomb]) was firstly constructed through mass arming two different anti-CD20 mAbs (RTX and tositumomab) to one polymer by nanotechnology. Comparing with free mAbs, PPRT nanocomb possesses a comparable binding ability and reduced “off-rate” to surface CD20 of NHL cells. When treated by PPRT nanocomb, the caspase-dependent apoptosis was remarkably enhanced except for concurrently eliciting complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and lysosome-mediated PCD. Besides, “cross-cell link”-assisted homotypic adhesion by PPRT nanocomb further enhanced the susceptibility to PCD of lymphoma cells. Pharmacokinetic assays revealed that PPRT nanocomb experienced a relatively reduced clearance from peripheral blood compared with free antibodies. With the cooperation of all the abovementioned superiorities, PPRT nanocomb exhibits exceptionally excellent in vivo antitumor activities in both disseminated and localized human NHL xenotransplant models.Keywords: non-Hodgkin lymphoma, CD20, nanotechnology, rituximab, programmed cell deathhttp://www.dovepress.com/construction-and-characterization-of-an-anti-cd20-mab-nanocomb-with-ex-peer-reviewed-article-IJN |
| spellingShingle | Li H Wu C Chen T Zhang G Zhao H Ke C Xu Z, Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity International Journal of Nanomedicine |
| title | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| title_full | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| title_fullStr | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| title_full_unstemmed | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| title_short | Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity |
| title_sort | construction and characterization of an anti cd20 mab nanocomb with exceptionally excellent lymphoma suppressing activity |
| url | http://www.dovepress.com/construction-and-characterization-of-an-anti-cd20-mab-nanocomb-with-ex-peer-reviewed-article-IJN |
| work_keys_str_mv | AT lih constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT wuc constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT chent constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT zhangg constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT zhaoh constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT kec constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity AT xuz constructionandcharacterizationofananticd20mabnanocombwithexceptionallyexcellentlymphomasuppressingactivity |